Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

Stock Information for Enveric Biosciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Enveric Biosciences Inc.

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
Enveric Biosciences Announces Participation in 2026 BIO International Convention
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.